東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Developments in T cell based cancer ...

Ascierto, Paolo A.

FindBook

Google Book

Amazon

博客來

Developments in T cell based cancer immunotherapies

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Developments in T cell based cancer immunotherapies/ edited by Paolo A. Ascierto, David F. Stroncek, Ena Wang.
其他作者:	Ascierto, Paolo A.
出版者:	Cham :Springer International Publishing : : 2015.,
面頁冊數:	xv, 305 p. :ill., digital ;24 cm.
內容註:	1 New insight of peptide vaccination in cancer immunotherapy -- 2 The determinants of T cell function for effective anticancer vaccine -- 3 T cell fate in the tumor microenvironment -- 4 T cell receptor avidity and affinity and tumor specific TCR engineer -- 5 Host genetic variation and somatic alteration associated with favorable or compromised T cell function -- 6 Production of Clinical T Cell Therapies -- 7 Clinical success of adoptive cell transfer therapy using tumor infiltrating lymphocytes -- 8 Harnessing stem cell-like memory T cells for adoptive cell transfer therapy of cancer -- 9 T cell blockade- anti-CTLA4 immunotherapy against cancer and Abscopal effect in combination therapy -- 10 T cell modulation- anti-OD-1 antibodies for the treatment of cancer -- 11 T cell based therapies in combination with other procedures -- 12 Chimeric antigen receptor T cells CD19 CAR -- 13 Hematopoietic Stem Cell transplantation as immune therapy of malignancies.
Contained By:	Springer eBooks
標題:	Cancer - Immunotherapy. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-21167-1
ISBN:	9783319211671

Developments in T cell based cancer immunotherapies
Developments in T cell based cancer immunotherapies[electronic resource] /edited by Paolo A. Ascierto, David F. Stroncek, Ena Wang. - Cham :Springer International Publishing :2015. - xv, 305 p. :ill., digital ;24 cm. - Cancer drug discovery and development,2196-9906. - Cancer drug discovery and development..

1 New insight of peptide vaccination in cancer immunotherapy -- 2 The determinants of T cell function for effective anticancer vaccine -- 3 T cell fate in the tumor microenvironment -- 4 T cell receptor avidity and affinity and tumor specific TCR engineer -- 5 Host genetic variation and somatic alteration associated with favorable or compromised T cell function -- 6 Production of Clinical T Cell Therapies -- 7 Clinical success of adoptive cell transfer therapy using tumor infiltrating lymphocytes -- 8 Harnessing stem cell-like memory T cells for adoptive cell transfer therapy of cancer -- 9 T cell blockade- anti-CTLA4 immunotherapy against cancer and Abscopal effect in combination therapy -- 10 T cell modulation- anti-OD-1 antibodies for the treatment of cancer -- 11 T cell based therapies in combination with other procedures -- 12 Chimeric antigen receptor T cells CD19 CAR -- 13 Hematopoietic Stem Cell transplantation as immune therapy of malignancies.

This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification or reprogramming to increase their ability to survive and expand when adoptively transferred back to the patients. Specific attention is devoted to the genetic manipulation of T cells through the introduction of re-directed T cell receptors, chimeric antibody receptors, and other genetic manipulation aimed at improving their effectiveness as anti-cancer agents. Furthermore, the revolutionary role of checkpoint inhibitors and their potential in combination with other immunotherapeutic approaches or with standard chemo and radiation therapy are extensively discussed.

ISBN: 9783319211671

Standard No.: 10.1007/978-3-319-21167-1doiSubjects--Topical Terms:

656051
Cancer
--Immunotherapy.

LC Class. No.: RC271.I45

Dewey Class. No.: 616.99406

Developments in T cell based cancer immunotherapies
LDR:03062nmm a2200325 a 4500 001 2013640
003 DE-He213
005 20160408171134.0
006 m d
007 cr nn 008maaau
008 160518s2015 gw s 0 eng d
020 $a 9783319211671 $q (electronic bk.)
020 $a 9783319211664 $q (paper)
024 7 $a 10.1007/978-3-319-21167-1 $2 doi
035 $a 978-3-319-21167-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.I45
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.99406 $2 23
090 $a RC271.I45 $b D489 2015
245 0 0 $a Developments in T cell based cancer immunotherapies $h [electronic resource] / $c edited by Paolo A. Ascierto, David F. Stroncek, Ena Wang.
260 $a Cham : $b Springer International Publishing : $b Imprint: Humana Press, $c 2015.
300 $a xv, 305 p. : $b ill., digital ; $c 24 cm.
490 1 $a Cancer drug discovery and development, $x 2196-9906
505 0 $a 1 New insight of peptide vaccination in cancer immunotherapy -- 2 The determinants of T cell function for effective anticancer vaccine -- 3 T cell fate in the tumor microenvironment -- 4 T cell receptor avidity and affinity and tumor specific TCR engineer -- 5 Host genetic variation and somatic alteration associated with favorable or compromised T cell function -- 6 Production of Clinical T Cell Therapies -- 7 Clinical success of adoptive cell transfer therapy using tumor infiltrating lymphocytes -- 8 Harnessing stem cell-like memory T cells for adoptive cell transfer therapy of cancer -- 9 T cell blockade- anti-CTLA4 immunotherapy against cancer and Abscopal effect in combination therapy -- 10 T cell modulation- anti-OD-1 antibodies for the treatment of cancer -- 11 T cell based therapies in combination with other procedures -- 12 Chimeric antigen receptor T cells CD19 CAR -- 13 Hematopoietic Stem Cell transplantation as immune therapy of malignancies.
520 $a This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification or reprogramming to increase their ability to survive and expand when adoptively transferred back to the patients. Specific attention is devoted to the genetic manipulation of T cells through the introduction of re-directed T cell receptors, chimeric antibody receptors, and other genetic manipulation aimed at improving their effectiveness as anti-cancer agents. Furthermore, the revolutionary role of checkpoint inhibitors and their potential in combination with other immunotherapeutic approaches or with standard chemo and radiation therapy are extensively discussed.
650 0 $a Cancer $x Immunotherapy. $3 656051
650 0 $a Medicine. $3 641104
650 0 $a Cancer $x Research. $3 696466
650 0 $a Immunology. $3 611031
650 0 $a Molecular biology. $3 517296
650 0 $a Cytology. $3 516274
650 1 4 $a Biomedicine. $3 890831
650 2 4 $a Cancer Research. $3 891172
650 2 4 $a Molecular Medicine. $3 890952
650 2 4 $a Cell Biology. $3 892383
700 1 $a Ascierto, Paolo A. $3 2163163
700 1 $a Stroncek, David F. $3 2163164
700 1 $a Wang, Ena. $3 1531037
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Cancer drug discovery and development. $3 1565408
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-21167-1
950 $a Medicine (Springer-11650)